Zachariae H, Ellegaard J, Grunnet E, Thestrup-Pedersen K
Dermatologica. 1980;160(1):1-6. doi: 10.1159/000250459.
13 patients with clinically and histologically verified mycosis fungoides were treated with transfer factor as additional therapy to the hitherto conventional treatment after this had failed. After approximately 3 years, complete remission was present in 3 patients, 4 patients were significantly improved and registered as being in partial remission, while the condition was registered as no change in 3 patients. 1 patient was found worse, 1 patient had died after discontinuation of therapy and 1 patient was out of the study. In this case treatment was withdrawn because of the development of contact urticaria to nitrogen mustard, her basic therapy. The number of T lymphocytes, which was low prior to treatment, increased to normal values during the therapeutic period. During the first year a decrease in serum IgE was noted. The results of the clinical evaluation seem to indicate that transfer factor may be of value as an additional therapeutic agent in mycosis fungoides. Controlled investigations are needed and are in progress.
13例经临床和组织学确诊为蕈样肉芽肿的患者，在既往常规治疗失败后，将转移因子作为附加治疗手段。约3年后，3例患者完全缓解，4例患者显著改善并登记为部分缓解，3例患者病情无变化。1例患者病情恶化，1例患者在治疗中断后死亡，1例患者退出研究。该病例因对其基础治疗药物氮芥发生接触性荨麻疹而停止治疗。治疗前数量较低的T淋巴细胞在治疗期间增至正常水平。在第一年观察到血清IgE下降。临床评估结果似乎表明，转移因子作为蕈样肉芽肿的附加治疗药物可能具有价值。需要且正在进行对照研究。
